184 related articles for article (PubMed ID: 23091276)
1. Covalent and non-covalent reversible proteasome inhibition.
Beck P; Dubiella C; Groll M
Biol Chem; 2012 Oct; 393(10):1101-20. PubMed ID: 23091276
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Huber EM; Groll M
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitors: Dozens of molecules and still counting.
de Bettignies G; Coux O
Biochimie; 2010 Nov; 92(11):1530-45. PubMed ID: 20615448
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z
Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
[TBL] [Abstract][Full Text] [Related]
7. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
Dalla Via L; Nardon C; Fregona D
Future Med Chem; 2012 Mar; 4(4):525-43. PubMed ID: 22416778
[TBL] [Abstract][Full Text] [Related]
8. Proteasome deubiquitinases as novel targets for cancer therapy.
D'Arcy P; Linder S
Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
[TBL] [Abstract][Full Text] [Related]
9. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
[TBL] [Abstract][Full Text] [Related]
11. Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors.
Maréchal X; Pujol A; Richy N; Genin E; Basse N; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2012 Jun; 52():322-7. PubMed ID: 22440858
[TBL] [Abstract][Full Text] [Related]
12. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome.
Groll M; Götz M; Kaiser M; Weyher E; Moroder L
Chem Biol; 2006 Jun; 13(6):607-14. PubMed ID: 16793518
[TBL] [Abstract][Full Text] [Related]
13. Novel organic proteasome inhibitors identified by virtual and in vitro screening.
Basse N; Montes M; Maréchal X; Qin L; Bouvier-Durand M; Genin E; Vidal J; Villoutreix BO; Reboud-Ravaux M
J Med Chem; 2010 Jan; 53(1):509-13. PubMed ID: 19919035
[TBL] [Abstract][Full Text] [Related]
14. Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition.
Groll M; McArthur KA; Macherla VR; Manam RR; Potts BC
J Med Chem; 2009 Sep; 52(17):5420-8. PubMed ID: 19678642
[TBL] [Abstract][Full Text] [Related]
15. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
Dick LR; Fleming PE
Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.
Tsukamoto S; Yokosawa H
Planta Med; 2010 Aug; 76(11):1064-74. PubMed ID: 20186654
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach.
Groll M; Huber R
Biochim Biophys Acta; 2004 Nov; 1695(1-3):33-44. PubMed ID: 15571807
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors mechanism; source for design of newer therapeutic agents.
Harer SL; Bhatia MS; Bhatia NM
J Antibiot (Tokyo); 2012 Jun; 65(6):279-88. PubMed ID: 22511225
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibitors of proteasome activity.
Gaczynska M; Osmulski PA
Methods Mol Biol; 2005; 301():3-22. PubMed ID: 15917622
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways: targeting proteasomal protein degradation in cancer.
Molineaux SM
Clin Cancer Res; 2012 Jan; 18(1):15-20. PubMed ID: 22019514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
